LBPH

Longboard Pharmaceuticals, Inc.

A clinical-stage biopharmaceutical company developing oral medicines for severe neurological conditions, particularly rare childhood epilepsies. Its lead candidate, bexicaserin (LP352), is a serotonin-based drug designed to reduce seizures in Dravet syndrome and Lennox-Gastaut syndrome, two hard-to-treat epilepsy forms. The company got its name from longboarding, the skateboard-style hobby of its founders, who met in California and named the venture after the sport that brought them together.

No proxy statement recorded.